Our Platform

Our Approach

TargImmune’s novel Ta:RNA™ platform harnesses the body’s powerful antiviral defence responses to selectively target and destroy cancer cells. This unique technology and innovative therapeutic approach have the potential to transform outcomes for cancer patients, whether used alone or in combination with existing treatments.

Despite significant advances in cancer treatments over the past decades, there are still gaps across classes of anti-cancer therapies. Whether they’re driving resistance, lack efficacy against ‘cold’ tumours, fail to deal with heterogeneous tumours, or show efficacy in only small patient populations, cancer patients could benefit from a new approach.

TargImmune’s therapeutics are the first in a new class - known as targeted apoptosis and immune modulators (TAIMs) - that addresses these limitations.

Survival rates image

Our Platform

The Ta:RNA™ platform uses double-stranded RNA (dsRNA) which is protected and guided within a targeted nanoparticle to selectively bind to the target receptor and trigger the destruction of cancer cells. The Ta:RNA™ platform can be targeted to a wide range of solid tumours over-expressing specific receptors.

By harnessing the body’s powerful antiviral defence responses, mimicking the natural process of viral infection, Ta:RNA™ drives a potent combination of apoptosis (cell death) and immune cell activation to target both primary and metastatic heterogeneous tumours.

Our targeted apoptosis and immune modulators (TAIMs) are designed to be delivered by systemic injection. This allows them to reach distant metastases, which are the leading cause of cancer death.

Our Focus

The TargImmune team are focused on improving the survival of cancer patients.

Our Ta:RNA™ platform is currently being developed for multiple solid tumour indications, including:

If successful, we believe we have the potential to transform outcomes for tens of thousands of patients each year.